Target Name: TEX101
NCBI ID: G83639
Review Report on TEX101 Target / Biomarker Content of Review Report on TEX101 Target / Biomarker
TEX101
Other Name(s): SGRG | TES101-reactive protein | testis expressed sequence 101 | TX101_HUMAN | cancer/testis antigen 131 | testis-specific protein TES101RP | CT131 | testis-expressed sequence 101 protein | TEX101 variant 1 | cell surface receptor NYD-SP8 | GTPR867 | testis expressed 101 | scleroderma-associated autoantigen | Scleroderma-associated autoantigen | Spermatogenesis-related gene protein | Testis expressed sequence 101 | SPATA44 | spermatogenesis-related gene protein | Cell surface receptor NYD-SP8 | TES101RP | Testis-expressed protein 101 | MGC4766 | NYD-SP8 | Testis-expressed protein 101 (isoform 1) | Testis-specific protein TES101RP | Testis expressed 101 | PRO1884 | spermatogenesis associated 44

TEX101: A Potential Drug Target and Biomarker for Alzheimer's

TEX101 (SGRG) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the neurotransmitter system, which is responsible for transmitting signals between the brain and other parts of the body.

Recent studies have identified TEX101 as a potential drug target (or biomarker) for the treatment of Alzheimer's disease. By blocking the activity of TEX101, researchers have found that they can reduce the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease, and slow down the progression of the disease.

In addition to its potential as a drug target, TEX101 has also been identified as a potential biomarker for Alzheimer's disease. Studies have shown that TEX101 levels are significantly reduced in the brains of people with Alzheimer's disease, and that levels increase in the pre-clinical stages of the disease. This suggests that TEX101 could be used as a diagnostic tool for Alzheimer's disease and as a target for new treatments.

EXCLUSIVE CONTENT FOR YOUR PERSONALIZED ARTICLE:

As the research on TEX101 continues to grow, it is clear that this protein has the potential to be a significant drug target and biomarker for Alzheimer's disease. By studying its role in the neurotransmitter system and its potential as a drug and biomarker, researchers are working to develop new treatments for this debilitating and progressive disease.

In the future, TEX101 may be used to treat Alzheimer's disease by blocking its activity and reducing the formation of beta-amyloid plaques. Additionally, it may be used as a diagnostic tool to detect the early stages of the disease and as a target for new treatments.

As with any new treatment, it is important to note that more research is needed before TEX101 can be considered a reliable and effective treatment for Alzheimer's disease. However, the potential benefits of TEX101 as a drug and biomarker are significant and continue to be the subject of ongoing research.

Overall, TEX101 is a promising protein that has the potential to revolutionize our understanding of Alzheimer's disease and its treatment. As research continues to progress, it is clear that TEX101 is an important protein to study and may have significant implications for the treatment of this debilitating and progressive disease.

Protein Name: Testis Expressed 101

Functions: Plays a role in fertilization by controlling binding of sperm to zona pellucida and migration of spermatozoa into the oviduct (By similarity). May play a role in signal transduction and promote protein tyrosine phosphorylation (By similarity)

The "TEX101 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TEX101 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3 | TGFBR3L | TGFBRAP1 | TGIF1 | TGIF2 | TGIF2-RAB5IF | TGIF2LX | TGIF2LY | TGM1 | TGM2 | TGM3 | TGM4 | TGM5 | TGM6 | TGM7 | TGOLN2